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Prognosis of carotid dissecting aneurysms
Results from CADISS and a systematic review
ABSTRACT
Objective: To determine the natural history of dissecting aneurysm (DA) and whether DA is asso-
ciated with an increased recurrent stroke risk and whether type of antithrombotic drugs (antipla-
telets vs anticoagulants) modifies the persistence or development of DA.
Methods: We included 264 patients with extracranial cervical artery dissection (CAD) from the
Cervical Artery Dissection in Stroke Study (CADISS), a multicenter prospective study that com-
pared antiplatelet with anticoagulation therapy. Logistic regression was used to estimate age-
and sex-adjusted odds ratios. We conducted a systematic review of published studies assessing
the natural history of DA and stroke risk in patients with non-surgically-treated extracranial CAD
with DA.
Results: In CADISS, DA was present in 24 of 264 patients at baseline. In 36 of 248 patients with
follow-up neuroimaging at 3 months, 12 of the 24 baseline DAs persisted, and 24 new DA had
developed. There was no association between treatment allocation (antiplatelets vs anticoagu-
lants) and whether DA at baseline persisted at follow-up or whether new DA developed. During
12 months of follow-up, stroke occurred in 1 of 48 patients with DA and in 7 of 216 patients
without DA (age- and sex-adjusted odds ratio 0.84; 95% confidence interval 0.10–7.31; p 5
0.88). Published studies, mainly retrospective, showed a similarly low risk of stroke and no
evidence of an increased stroke rate in patients with DA.
Conclusions: The results of CADISS provide evidence suggesting that DAsmay have benign prog-
nosis and therefore medical treatment should be considered. Neurology® 2017;88:646–652
GLOSSARY
CAD5 cervical artery dissection; CADISS5 Cervical Artery Dissection in Stroke Study; CI5 confidence interval; CTA5 CT
angiography; DA 5 dissecting aneurysm; ICA 5 internal carotid artery; MRA 5 magnetic resonance angiography; NR 5
nonrandomized; OR 5 odds ratio; VA 5 vertebral artery.
Cervical artery dissection (CAD) is an important cause of stroke in younger adults.1 A common
angiographic consequence is dissecting aneurysm (DA), also called false or pseudoaneurysm,
occurring in 13%–49% of patients with CAD.2–12 It has been suggested that DAs indicate
increased stroke risk, either as a source of embolization or via expansion and compressive
symptoms. This has led some specialists to treat DA; in a recent study, 20% were obliterated
with stenting and coiling.12 Other authorities suggest the risk of stroke in CAD is low and no
treatment is required. Small studies report low stroke risk,4–7,10 but these are retrospective with
incomplete case ascertainment. Data from prospective studies with predefined clinical and
imaging follow-up protocols are limited.11
The Cervical Artery Dissection in Stroke Study (CADISS) was a randomized controlled trial
comparing antiplatelet with anticoagulant therapy in CAD.13,14 In addition, patients who did
not meet the inclusion criteria or where the patient or doctor were not prepared to randomize
were recruited to the nonrandomized arm.15 Angiographic imaging was reviewed at baseline and
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repeated in the majority of participants at 3
months. This provides robust data from a pro-
spective study on the prevalence and outcome
of DA.
We determined the incidence and risk
factors for DA in CADISS, their natural history
on angiographic imaging, and whether they
were associated with an increased recurrent
stroke risk. We also examined whether type
of antithrombotic drugs (antiplatelets vs anti-
coagulants) was associated with the persistence
or development of DA. In addition, we per-
formed a systematic review of published studies
assessing the natural history of DA and stroke
risk in patients with non-surgically-treated
extracranial CAD with DA.
METHODS Participants. CADISS was a multicenter
prospective study comparing anticoagulation with antiplatelet
therapy in patients with CAD. Full details with follow-up to
the 3-month primary endpoint have been published
previously.13,14 A total of 250 patients were randomized 1:1 via
an automated 24-hour telephone randomization service to
a treatment regimen of antiplatelet agents or anticoagulants for
3 months in an open design with blinded evaluation of endpoints.
Inclusion criteria were extracranial carotid or vertebral artery
dissection with symptom onset within the last 7 days, in
combination with imaging evidence of definite or probable
dissection. If the patient had had a stroke or TIA within the
last 7 days he or she was eligible even if this was preceded by
local symptoms with onset more than 7 days previously. Imaging
evidence of definite or probable dissection had to be on MRI/
magnetic resonance angiography (MRA), CT angiography
(CTA), or intra-arterial angiography. Exclusion criteria were
intracranial cerebral artery dissection; contraindications to
antiplatelet agents or anticoagulation therapy, including active
peptic ulceration or bleeding peptic ulcer within 1 year; patient
refusal to consent; patient already taking antiplatelet agents or
anticoagulants for other reasons; and pregnancy. Patients not
eligible for inclusion in the randomized arm, or where the
doctor or patient did not accept randomization, were recruited
to the nonrandomized arm (CADISS-NR) if they were within 31
days of symptom onset.15 Patients in CADISS-NR underwent the
same imaging and clinical follow-up protocol.
Standard protocol approvals, registrations, and patient
consents. The local ethics committee approved the study, and all
patients provided written consent.
Data collection and outcome assessment. Patients were seen
in person for follow-up at 3 months postrandomization. Data on
outcome and occurrence of recurrent stroke and TIA were
recorded. Repeat imaging with MRA or CTA was performed
Table 1 Number (%) of patients with dissecting aneurysm (DA) at baseline and 3 months in the Cervical Artery Dissection in Stroke Study
DA
In 264 patients with imaging at baseline In 248 patients with follow-up imaging at 3 months
Baseline Baseline 3 months
All ICA VA All ICA VA All ICA VA
Yes 24 (9.1) 13 (10.6) 11 (7.8) 24 (9.7) 13 (11.3) 11 (8.3) 36 (14.5) 21 (18.3) 15 (11.3)
No 240 (90.9) 110 (89.4) 130 (92.2) 224 (90.3) 102 (88.7) 122 (91.7) 212 (85.5) 94 (81.7) 118 (88.7)
Abbreviations: ICA 5 internal carotid artery; VA 5 vertebral artery.
Table 2 Characteristics of patients with and without dissecting aneurysm (DA) at baseline or 3 months in the Cervical Artery Dissection in
Stroke Study
Characteristica
DA at baseline or 3 months No DA at any time point
p ValuebAll (48) ICA (27) VA (21) All (216) ICA (96) VA (120)
Age, y 44.7 (10.3) 47.6 (8.8) 41.1 (11.1) 47.6 (11.9) 46.0 (10.4) 48.8 (12.9) 0.13
Female 15 (31.3) 8 (29.6) 7 (33.3) 77 (35.6) 37 (38.5) 40 (33.3) 0.56
Treated hypertension 7 (14.6) 4 (14.8) 3 (14.3) 47 (21.8) 16 (16.7) 31 (25) 0.27
Diabetes mellitus 1 (2.1) 1 (3.7) 0 (0) 9 (4.2) 3 (3.1) 6 (5.0) 0.49
Current smoker 7 (14.6) 4 (14.8) 3 (14.3) 54 (25.0) 26 (27.1) 28 (23.3) 0.12
Statin therapy 6 (12.5) 5 (18.5) 1 (4.8) 48 (22.2) 23 (24.0) 25 (20.8) 0.13
History of recent trauma (<30 d) 15 (31.3) 8 (29.6) 7 (33.3) 50 (23.3) 25 (26.0) 25 (20.8) 0.25
Migraine 9 (18.8) 6 (22.2) 3 (14.3) 40 (18.6) 21 (21.9) 19 (15.8) 0.99
Thrombolysis for stroke 5 (10.4) 4 (14.8) 1 (4.8) 17 (7.9) 10 (10.4) 7 (5.8) 0.57
Abbreviations: ICA 5 internal carotid artery; VA 5 vertebral artery.
aData are presented as n (%), except for age, which is presented as mean (SD).
bp Value for difference in baseline characteristic for all patients without DA vs all patients with DA at any point.
Neurology 88 February 14, 2017 647
ª 2017 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
whenever possible at 3 months to assess vessel recanalization. All
radiology images at baseline and 3 months were reviewed by
a consultant neuroradiologist in the coordinating center who
was blinded to treatment allocation. Telephone follow-up was
performed at 6 and 12 months and in cases of possible stroke
original records and scans were reviewed. All stroke cases were
adjudicated by a committee blinded to patient treatment and
the results of angiographic imaging.
Participants included in the present analysis. On central
radiology review, there were confirmatory features of a dissection
in 197 of 250 patients, and in 1 additional patient; although the
patient was recruited within 7 days, due to a technical problem
with the randomization process, randomization itself occurred
on day 9. Therefore 197 patients were included in the analysis,
in addition to 67 patients with centrally confirmed imaging
appearances of dissection in the NR arm. These 264 patients were
included in the present analysis. Follow-up was complete at 1 year
in all 264 patients.
Statistical analysis. Characteristics of patients with and without
DA were compared using t and x2 tests. Logistic regression was
used to estimate age- and sex-adjusted odds ratios (ORs) with
95% confidence intervals (CIs). The statistical analyses were
performed using Stata version 14.1 (StataCorp, College Station,
TX). All tests were 2-sided and p values , 0.05 were considered
statistically significant.
Systematic review. Relevant studies were identified by searches
of PubMed (including MEDLINE) from inception to October
15, 2016, using the search terms carotid artery, vertebral artery,
or extracranial artery combined with pseudoaneurysms, dissecting
aneurysms, or false aneurysms. No language or other restrictions
were imposed. The reference lists of retrieved publications were
reviewed to search for additional studies. Two authors (S.C.L.,
A.K.) performed the literature search. Inclusion criteria were
(1) prospective or retrospective longitudinal study; and (2) re-
ported results on anatomical or clinical outcome of aneurysmal
forms of extracranial CAD in medically treated patients. Exclu-
sion criteria were intracranial CAD, invasive treatment of pa-
tients, fewer than 5 patients with extracranial CAD with DA,
case-report, case-control, or cross-sectional study, nonhuman
study, and other nonrelevant reports not meeting the inclusion
criteria.
Data were extracted independently by 2 authors (S.C.L.,
H.S.M.), and any disagreement was resolved by consensus. The
following information was extracted: last name of the first author,
publication year, study design (prospective or retrospective),
number of patients, mean age of patients, mean follow-up time,
imaging modality for follow-up, time between symptom and
angiography, number of dissecting aneurysms and affected vessel,
anatomical findings from follow-up imaging, and clinical out-
come events (any fatal or nonfatal stroke).
Data on the presence and anatomical outcome of DA were
only taken from studies that performed angiographic imaging at
baseline and follow-up with CTA, MRA, or digital subtraction
angiography. Studies with Doppler ultrasound alone follow-up
were not included as this has a low sensitivity for detecting DA.
RESULTS CADISS.On central imaging review, a DA
was present in 24 (9.1%) of the 264 patients at base-
line (table 1). Follow-up MRA or CTA at 3 months
was present and of adequate quality for central
radiologic review for 248 of the 264 patients.
Analysis of these 248 patients showed that DA was
present at baseline in 24 (9.7%). At a median follow-
up of 3.2 months (interquartile range 3.0–3.5
months), 12 (6 internal carotid artery [ICA] and 6
vertebral artery [VA]) of the 24 baseline DAs persisted
whereas 12 DAs (7 ICA and 5 VA) had resolved. In
addition, 24 new DAs (14 ICA and 10 VA) had
developed. Patients with and without DA did not
differ significantly with regard to age, sex, vascular
Table 3 Associations of antiplatelet and anticoagulant therapywith persistence of dissecting aneurysm (DA) and development of newDA at 3
months follow-up in the Cervical Artery Dissection in Stroke Study
Outcome Antiplatelet therapy (n 5 139) Anticoagulant therapy (n 5 109) Unadjusted OR (95% CI) Adjusted OR (95% CI)a p Valuea
Persistent DA 8/14 (57)b 4/10 (40)b 0.50 (0.10–2.60) 0.57 (0.09–3.51) 0.54
New DA 12/125 (10)b,c 12/99 (12)b,c 1.33 (0.66–2.70) 1.34 (0.66–2.71) 0.42
Abbreviations: CI 5 confidence interval; OR 5 odds ratio.
a Adjusted for age and sex.
bNumber of patients with persistent DA or new DA/total number of patients in the group (% with persistent DA or new DA).
c Excluding patients with DA at baseline.
Figure Flowchart of study selection
CAD 5 cervical artery dissection; DA 5 dissecting aneurysm.
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Table 4 Previous studies of anatomic outcome of dissecting aneurysms (DAs) due to cervical artery dissection in medically treated patients
Reference Study design
Imaging
modality for
DA diagnosis
Mean time
between
repeated
imaging, mo Patient population
Dissecting
aneurysms Angiographic findings for ICAa Angiographic findings for VAb
Total
DA ICA VA Unchanged Resolved Decreased Enlarged Unchanged Resolved Decreased Enlarged
16 Retrospectiveb CA/DSA 64 Spontaneous 18 20 0 6 (33) 4 (22) 8 (45) 0
40 Traumatic 12 14c 0 5 (63) 1 (12) 2 (25) 0 — — — —
17 Retrospective CA/CTA 24 Symptomatic 8 8 0 4 (50) 4 (50) 0 0 — — — —
4 Retrospective CA/MRA 37 Symptomatic ,30 days 20 20 0 13 (65) 1 (5) 6 (30) 0 — — — —
5 Retrospective MRA 41 Symptomatic mostly ,30 days 26 26 0 20 (77) 2 (8) 4 (15) 0 — — — —
6 Recall of prospectively
recruited cohort
MRA 42 Symptomatic arteries 28 22 6 10 (46) 8 (36) 4 (18) 0 1 (17) 5 (83) 0 0
Asymptomatic arteries 12 10 2 9 (90) 0 1 (10) 0 0 2 (100) 0 0
7 Retrospective DSA 4 Symptomatic (,28 days in
.90%)d
11 11 0 8 (73) 1 (9) 2 (18) 0 — — — —
18 Prospective and
retrospective components
CTA/DSA 22 Screening of patients presenting
with blunt trauma
26 25 1 1 (4) 10 (38) 10 (38) 5 (19) — — — —
19 Retrospective CTA/MRA Uncertain Asymptomatic 52 0 52 — — — — 50 (96) 5 1 (2) 1 (2)
Pain only 56 0 56 — — — — 38 (68) 0 15 (27) 3 (5)
Mass effect 5 0 5 — — — — 3 (60) — 1 (20) 1 (20)
12 Retrospective CTA/MRA Uncertain Uncertain 108e NA NA 60 (56)f 33 (30)f 0 15 (14)f — — — —
CADISS Prospective CTA/MRA 3 Symptomatic 24 13 11 6 (46) 7 (54) 0 0 6 (55) 5 (45) 0 0
Abbreviations: CA 5 conventional angiography; CTA 5 CT angiography; DSA 5 digital subtraction angiography; ICA 5 internal carotid artery; MRA 5 magnetic resonance angiography; NA 5 not available; VA 5
vertebral artery.
aData are reported as number (%) of dissecting aneurysms that were unchanged or had resolved, decreased, or enlarged during follow-up.
b This study included patients from Mokri et al.2 Because of overlapping case series only the most recent study by Mokri,16 which included more patients, was included.
c Four DAs were eliminated by resection.
dOne patient who had artery ligated was omitted from analysis.
e Including 18.3% intracranial dissecting aneurysms and 20.8% of patients received an intervention other than medical treatment.
f ICA and VA DAs combined.
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risk factors, history of recent trauma, or use of IV
thrombolysis (table 2). Treatment allocation
(antiplatelets vs anticoagulants) did not modify
whether DA at baseline persisted at the 3-month
follow-up or whether new DA developed (table 3).
Follow-up data to the final follow-up of 12 months
were obtained in all patients. Eight strokes (all ipsilat-
eral) occurred during follow-up in the 264 patients.
One of the events occurred in the 48 patients with
DA at baseline or 3 months, and 7 occurred in the
216 patients without DA (age- and sex-adjusted OR
0.84; 95% CI 0.10–7.31, p 5 0.88). There were
too few events to determine whether antiplatelets or
anticoagulants were more effective at preventing recur-
rent stroke in patients with DA: no stroke in 26 DA
patients treated with antiplatelets and 1 stroke in 22
DA patients treated with anticoagulants.
Systematic review. The literature search identified
4,725 articles, of which 12 studies met the inclusion
criteria (figure). Among the included studies, 9 pro-
vided data on anatomical outcome4–7,12,16–19 and 9
provided data on clinical outcome4–7,10–12,18,19 in pa-
tients with CAD with DA.
The definition used to define complete and partial
resolution differed between studies but the results
showed a very low rate of DA expansion with no cases
of expansion in 8 of the 9 studies (table 4). The
studies confirmed that many DAs resolved com-
pletely on follow-up imaging. The resolution rate
appeared to be higher in patients initially imaged
shortly after presentation and was lower in asymp-
tomatic DAs, suggesting that if DAs are to resolve
they tend to do so shortly after formation.
Seven studies provided outcome data in patients
with CAD with DA but had no comparison group
without DA4–6,10,12,18,19; combined, these studies
included 323 patients with DAs, of whom 3 had
a stroke (1 fatal and 1 capsular stroke in 1 study10
and 1 nonfatal ischemic stroke in another study19) dur-
ing follow-up (table 5). Only 2 studies compared clin-
ical outcome in patients with CAD and without DA7,11;
no strokes occurred in either group (table 5).
DISCUSSION In the prospective CADISS study, our
data demonstrate that DA is a relatively common
sequel to extracranial vessel dissection, has a benign
prognosis, and the presence of a DA does not indicate
that an individual with dissection is at higher risk of
recurrent stroke. Our data further suggest that DA
is a relatively dynamic process with a significant pro-
portion of aneurysms either healing or developing
over the initial 3 months following clinical diagnosis
of vessel dissection. There was no difference in the
Table 5 Studies of clinical outcome of dissecting aneurysm (DA) due to cervical artery dissection (CAD) in medically treated patients
Reference Study design
Mean
age, y Time since symptom onset
Mean follow-
up, mo
No. of CAD patients
No. of stroke cases
during follow-up in CAD
patients
Totala ICA VA With DA Without DA
4 Retrospective 47 ,30 days 36.9 16 16 0 0/16 NA
5 Retrospective 52 ,30 days and .30 days in 79%
and 21% of patients, respectively
41 20 20 0 0/20 NA
6 Recall of prospectively
recruited cohort (80%
response rate)
44 Mean 11.6 days 41.6 35 35 0 0/35 NA
7 Retrospective 45 Mean 7.2 days 4 11/80 NA NA 0/11 0/80
10 Retrospective 47 35/38 symptomatic; median 11
days and 9 months in 55% and
45% of patients, respectively
78 37 NA NA 2/37b NA
11 Prospective 42 29/33 symptomatic; 8 days 37 6/27 0 40 0/6 0/27
18 Prospective and
retrospective
components
32 Screening of patients presenting
with major blunt trauma
15.8 13 12 1 0/13c NA
19 Uncertain 55 Nonstroke; 52 asymptomatic,
56 pain, 5 mass effect
34.8 113 0 113 1/113d NA
12 Retrospective 48 NA 29.3 89e NA NA 0/89 NA
CADISS Prospective 47 ,7 days 12 48/216 27/96 21/120 1/48 7/216
Abbreviations: CADISS 5 Cervical Artery Dissection in Stroke Study; ICA 5 internal carotid artery; NA 5 not available; VA 5 vertebral artery.
a Number of patients with CAD with/without DA.
bOne patient who died of stroke at 14 days from initial stroke due to acute CAD was excluded.
cOne patient noted to have asymptomatic bilateral anterior cerebral artery infarct at 2 weeks on MRI.
d Two additional patients developed symptoms due to mass effect.
e ICA and VA DA patients combined. Only patients not undergoing neurobiological or surgical intervention included.
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persistence of DA or development of new DA for
antiplatelet vs anticoagulant therapy.
CADISS provides some of the most robust evi-
dence on the prognosis of DA. Its prospective design
and complete outcome ascertainment during follow-
up makes it much less susceptible to bias than previous
retrospective studies. During the 1-year follow-up,
there were few recurrent strokes, and stroke risk in pa-
tients who had a DA on either initial imaging or 3-
month imaging was no higher than those without
DA. CADISS also provides data on the anatomical
outcome of DA. The results showed that approxi-
mately half of all DA resolved entirely within the first
3 months, but that additional aneurysms appeared
after the initial angiographic imaging.
The results of both the follow-up angiographic
imaging and clinical follow-up in CADISS were
broadly in agreement with those from our systematic
review. This also showed a very low risk of recurrent
strokes in patients with DA. However, most previous
studies had significant limitations, including retro-
spective design and the potential for ascertainment
bias and variable inclusion criteria. In addition, in
some studies a proportion of patients had interven-
tions other than medical therapy, for example coiling
or surgical intervention.12
Despite their benign prognosis, a significant num-
ber of patients with DA are treated with interven-
tions, the most common being coiling, which has
an associated risk of stroke. Our data suggest that
such interventions may not be warranted and medical
treatment alone is sufficient, and indeed is likely to be
safer. In CADISS, all patients were on either antipla-
telet drugs or anticoagulants, and in the systematic
review most patients were on antithrombotic medica-
tion. It is therefore impossible to determine from the
available data whether patients with DA need long-
term antithrombotic medication. There are occa-
sional cases of DA where expansion occurs, resulting
in compressive symptoms. There were no such cases
in CADISS, and such complications appeared to be
very rare, but in these exceptional cases intervention
may be required.12
The results of CADISS provide robust evidence
that DAs may have a benign prognosis and therefore
medical treatment should be considered. This finding
is consistent with those from a systematic review of
previous largely retrospective observational studies.
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